Activation of cardiac fibroblasts into myofibroblasts is considered to play an essential role in cardiac remodeling and fibrosis. A limiting factor in studying this process is the spontaneous activation of cardiac fibroblasts when cultured on two-dimensional (2D) culture plates. In this study, a simplified three-dimensional (3D) hydrogel platform of contractile cardiac tissue, stimulated by transforming growth factor-β1 (TGF-β1), is presented to recapitulate a fibrogenic microenvironment. It is hypothesized that the quiescent state of cardiac fibroblasts can be maintained by mimicking the mechanical stiffness of native heart tissue. To test this hypothesis, a 3D cell culture model consisting of cardiomyocytes and cardiac fibroblasts encapsulated within a mechanically engineered gelatin methacryloyl hydrogel, is developed. The study shows that cardiac fibroblasts maintain their quiescent phenotype in mechanically tuned hydrogels. Additionally, treatment with a beta-adrenergic agonist increases beating frequency, demonstrating physiologic-like behavior of the heart constructs. Subsequently, quiescent cardiac fibroblasts within the constructs are activated by the exogenous addition of TGF-β1. The expression of fibrotic protein markers (and the functional changes in mechanical stiffness) in the fibrotic-like tissues are analyzed to validate the model. Overall, this 3D engineered culture model of contractile cardiac tissue enables controlled activation of cardiac fibroblasts, demonstrating the usability of this platform to study fibrotic remodeling.
Introduction
Cardiovascular diseases (CVDs), such as ischemic heart disease and hypertension, have remained in the top ten major causes of death worldwide. [1] Myocardial infarction (MI), which is responsible for more than 50% of the deaths attributable to CVDs, results in a significant loss of cardiomyocytes. [2, 3] This loss results in the initiation of a reparative wound healing process, which is characterized by an initial inflammatory phase and followed by the proliferation and activation of quiescent cardiac fibroblasts into cardiac myofibroblasts (MyoFs). [4] Cardiac fibrosis results from the excessive synthesis and accumulation of extracellular matrix (ECM) components (e.g., collagen, fibronectin), and is caused by the persistent activation and proliferation of both cardiac fibroblasts and MyoFs (Figure 1) . [3] [4] [5] [6] [7] [8] In addition, MyoFs (hallmarked by the expression of α-smooth muscle actin (α-SMA)) ( Figure 1 ) have contractile properties, which can lead to a sustained contractile stress that is exerted on the infarcted area. [9, 10] In the short term outlook, these pro-fibrotic processes can be beneficial for cardiac function as it prevents dilatation and rupturing of the ventricular wall. [11] However, prolonged excessive activity of MyoFs results in excessive fibrosis and tissue stiffening, which ultimately impairs cardiac function, increases the risk of arrhythmia, and leads to the progression of end-stage heart failure. [6, 9, 12, 13] Although there are many identified biochemical factors (e.g., transforming growth factor-β1 (TGF-β1), angiotensin II, endothelin-1, platelet derived growth factor), [4, 8, 14] mechanobiological, (e.g., tissue stiffness, mechanical strain, and hemodynamic stress) [15, 16] and cellular processes (e.g., cardiac fibroblasts migration, MyoF activation) [7] that play a crucial role in cardiac fibrosis, there are a limited number of therapies available that effectively target fibrosis associated heart disease. [8, 9, 17] An important cause of the limited development of improved and more specific therapies against cardiac fibrosis is the lack of biomimetic in vitro platforms to investigate the fibrogenic remodeling after cardiac injury. [4] A suitable in vitro model would preferably maintain cardiac fibroblasts in a quiescent state and enable the integration of more physiological factors, such as contractile tissue activity, cell-cell, cell-ECM, and paracrine and hormonal interactions. Thus there exists a need for a novel, in vitro model system to study the pathological changes in biomimetic and in vivo like conditions. These systems could not only be used for studying fibrotic changes in heart tissue, but they can potentially contribute to the development of more physiologically relevant in vitro assay systems for drug screening. [18] During the last decade, tissue engineering strategies have shown promise in designing biomimetic in vitro models of cardiac tissue through the use of cardiac cells encapsulated in three-dimensional (3D) hydrogelbased ECM. [19, 20] For instance, the use of a gelatin methacryloyl (GelMA)-based hydrogel in creating a functional and contractile cardiac tissue was demonstrated by the successful encapsulation of cardiomyocytes and cardiac fibroblasts in a gelatin-based hydrogel. [19, 21] In particular, Saini et al. have focused on developing and optimizing the co-culture conditions with cardiomyocytes and cardiac fibroblasts within GelMA hydrogels to create healthy and functional cardiac tissue constructs. [19] Despite the significant achievements in this area, the previously engineered 3D cardiac-like tissues have not been used to study the pathological remodeling that occurs during cardiac fibrosis. Furthermore, most commonly used model systems to study cardiac fibrosis were based on either two-dimensional (2D) [22] or monocultures of cardiac fibroblasts. [22, 23] However, several 3D culture models using different natural (e.g., collagen, hyaluronic acid) or synthetic-derived (e.g., polyethylene glycol (PEG)) hydrogels have been developed to control and direct the activation of cardiac fibroblasts and fibroblast-like cells into MyoFs using mechanobiological cues. [22] [23] [24] However, there are still remaining challenges in engineering cardiac-like tissues to study MyoF activation and the associated fibrotic remodeling. Consequently, to successfully resemble the fibrotic remodeling process, some of the crucial factors that need to be incorporated within in vitro culture platforms are different cardiac cells in an in vivo like 3D microenvironment, which can be stimulated (externally) to exhibit a more fibrosis phenotype. For example, a recent study found increased MyoF activation when cardiac fibroblasts were encapsulated within a stiff hydrogel condition, as opposed to Figure 1 . Schematic illustration of the pathophysiological changes during fibrotic cardiac remodeling. Healthy myocardial tissue consists of a network of cardiomyocytes (CMs) and quiescent cardiac fibroblasts (CF) that are interspersed within the extracellular matrix (ECM). After myocardial injury (e.g., myocardial infarct (MI)), cardiomyocytes die and a reparative inflammatory and wound healing process is initiated by the release of various cytokines and growth factors (such as TGF-β1, angiotensin-II, etc.). This results in the activation of cardiac fibroblasts into cardiac myofibroblasts (MyoFs). These cells and other resident cardiac fibroblasts are responsible for an excessive and prolonged synthesis and deposition of de novo ECM proteins (e.g., collagen-I, fibronectin, laminin). This results in scarring of the heart tissue and leads to the deterioration of ventricular function followed by diastolic and systolic ventricular dysfunction and may eventually lead to life threatening arrhythmogenicity or heart failure.
www.advancedsciencenews.com www.advhealthmat.de culturing the cells within softer matrices. [23] Additionally, a better functional and contractile phenotype is observed in cardiomyocytes when cultured on relatively softer hydrogel-based matrices. [25, 26] These studies have suggested that mechanical properties are a key factor in creating native-like heart tissues in vitro. Consequently, physiologically relevant mechanical cues should be incorporated into 3D matrices to fabricate a cardiac tissue model and to maintain cardiac fibroblasts in a quiescent state. Then biochemical components, such as TGF-β1, could be applied to activate the cardiac fibroblasts toward MyoFs to demonstrate an increased synthesis and deposition of ECM proteins (e.g., collagen-I, fibronectin) by TGF-β1 signaling.
In the present study, we developed a 3D hydrogel-platform, composed of primary cardiomyocytes and cardiac fibroblasts, which are used to engineer a physiologically relevant in vitro platform to control the activation of cardiac fibroblasts toward MyoFs. We hypothesized that by mechanically tuning the stiffness of the hydrogels, a native-like ECM environment can be created to enhance the quiescent state of cardiac fibroblasts, and the functional behavior of engineered cardiac tissues. Therefore, the concentration and degree of methacrylation of GelMA macromers, which are important parameters to tune the stiffness of the GelMA hydrogel, were optimized for mimicking the mechanical stiffness of native heart tissue, allowing cardiac fibroblasts to remain in a quiescent state. In addition, the physiological properties of these in vitro cardiac tissues were characterized and the pro-fibrotic consequences of a TGF-β1 induced activation of cardiac fibroblasts were observed. We believe that this disease model of myocardial fibrosis may be a suitable in vitro model to study bio-mechanistic processes of cardiac fibrosis. Moreover, this platform could contribute to the development of better biomimetic preclinical drug screening platforms.
Results

Engineering and Characterization of GelMA Scaffolds
The elastic moduli of a healthy neonatal rat heart ranges from ≈4 to 11 kPa. [25] In this study, we encapsulated cells from neonatal rat hearts in a GelMA-based hydrogel to engineer 3D myocardial tissues in vitro. The hydrogels showed an increased stiffness with increasing methacryloyl modification degree and macromer concentration (Figure 2A ). As such, 10% high-degree methacryloyl (HM)-GelMA hydrogel exhibited the highest mechanical stiffness (26 ± 6 kPa) compared to all other hydrogel conditions (p < 0.05). However, 7% HM-GelMA hydrogel (13 ± 2 kPa) showed a significantly higher compressive modulus than 7% middle-degree methacryloyl (MM)-GelMA hydrogel (4.5 ± 0.8 kPa) (p < 0.05) and a significantly lower compressive modulus when compared to 10% HMGelMA hydrogel. This confirms that the mechanical stiffness can be tuned by varying the methacryloyl modification degree and macromer concentration of GelMA independently. [21] The following three hydrogels 5% HM-GelMA (10 ± 4 kPa), 7% MM-GelMA (4.5 ± 0.8 kPa), and 10% MM-GelMA (7 ± 1 kPa), exhibited a mechanical stiffness that was within the range of native neonatal rat hearts ( Figure 2A ) and were therefore further characterized.
To access the effect of the GelMA macromer concentration and methacryloyl modification degree on the morphology of hydrogel, all scanning electron microscopy (SEM) samples were prepared by same cryogenic treatment. SEM images indicated that all three selected hydrogels showed highly microporous structure which were obtained by lyophilization ( Figure 2 ). [27] There was a significant decrease in porosity with an increased macromer concentration. In addition, a significantly lower porosity was observed in the 5% HM-GelMA hydrogel as compared to the 7% and 10% MM-GelMA hydrogels ( Figure 2B ). This indicates an inverse relationship between porosity and degree of methacryloyl modification and macromer concentration. Although there was a significant decrease in the porosity of 5% HM-GelMA hydrogel, no significant increase was observed in the mechanical properties of 5% HMGelMA hydrogel when compared to 7% and 10% MM-GelMA hydrogels ( Figure 2A ). In native cardiac tissue, matrix metalloproteinases (MMPs) are excreted and activated by cells to induce and promote the cleavage of ECM components. [28] These proteins play an important role in the maintenance and remodeling of the heart ECM. To assess the presence of physiological binding substrates for an MMP-mediated degradation of the GelMA-based scaffold, a degradation assay was performed with MMP-8 (also known as Collagenase type II). The results revealed significantly faster degradation-described as percentage of weight loss-of 5% HM-GelMA hydrogel after 3 and 6 h when compared to 10% MM-GelMA hydrogel (p < 0.05). Furthermore, a complete degradation of all three hydrogels was observed after 15 h of incubation with MMP-8 ( Figure 2C ). These results confirm the existence of MMP substrates in the GelMA hydrogel but also indicate the opportunity for use of GelMA-based scaffolds for engineered physiological heart ECM tissue.
GelMA Hydrogel Characteristics Affect Cell Spreading But Not Viability
To determine what hydrogel condition enabled the best cellular spreading and networking, we investigated the spreading of encapsulated cells inside the three selected GelMA hydrogels. To visualize this, fluorescent confocal z-stack images were taken after F-actin (cytoskeletal fiber) staining of the cell-laden hydrogels ( Figure 3A) . After 10 d of culture, the fluorescence images demonstrated that the majority of the cells inside 5% HMGelMA and 10% MM-GelMA hydrogels had limited spreading, as the cells retained a round shape. Interestingly, the expression of F-actin fibers throughout the 7% MM-GelMA hydrogel clearly demonstrated an increase in cellular spreading and networking ( Figure 3A) . A higher cellular spreading was expected due to a lower methacryloyl modification degree and macromer concentration, thereby allowing for an increased degradation and spreading throughout the ECM by the cells. Therefore, a higher cellular spreading and networking in 7% MM-GelMA hydrogel could be attributed to the lower macromer concentration and degree of methacryloyl modification as compared to 10% MM-GelMA and 5% HM-GelMA hydrogels, respectively. Additionally, a quantitative analysis of the area covered by F-actin fibers confirmed a significantly higher percentage of fractional coverage in 7% MM-GelMA hydrogel (75 ± 18%) compared to 5% HM-GelMA (23 ± 5%) and 10% MM-GelMA (43 ± 9%) hydrogels at day 10 of culture (p < 0.05) ( Figure 3B ). The viability of encapsulated cells in the different conditions was also assessed after 1 d of culture. This time point was chosen to evaluate the survival of cells following UV exposure during the fabrication of the constructs. Figure 3C depicts the quantitative analysis of the percentage of live cells at day 1 of culture. Across all experimental conditions, the percentage of live cells was higher than 84% and was not significantly different between groups.
Functional Properties of the 3D Engineered Cardiac Tissues
For further experiments, we selected the 7% MM-GelMA hydrogel for having the best spreading and networking features for the cells. Additionally, we studied the viability of cells in this condition for two weeks of culture. The results revealed that the engineered cardiac tissues remained viable throughout a culture period of 14 d (Figure 4A ). Compared to day 1, there was a significant increase in the metabolic activity after 14 d ( Figure 4A ) (p < 0.05). Given the fact that cardiomyocytes have a limited proliferative capacity, [19] we believe that cardiac fibroblasts were responsible for the increase in metabolic activity.
On day 14, we also assessed the phenotype of the encapsulated cardiomyocytes and cardiac fibroblasts by immunostaining with sarcomeric α-actinin and vimentin. As depicted in Figure 4B , a confocal z-stack image of an immunostained cellladen GelMA hydrogel displayed both sarcomeric α-actinin and vimentin positive cells. In addition, we investigated the expression of connexin-43, a gap junction protein that is important for electrical coupling of cardiomyocytes and is typically found in the cardiac tissue. [29] From the confocal image in Figure 4C , it is clear that cardiomyocytes demonstrated the expression of both connexin-43 and sarcomeric α-actinin. The expression of gapjunctions and functional electro-mechanical coupling was also confirmed by the observation of spontaneous, synchronous, and cardiac tissue-like contraction of the engineered 3D cardiac tissues (Video S1, Supporting Information). Spontaneous individual cell beating activity began after 2 d of culture; however, videos of the beating were recorded and analyzed from when synchronous and tissue-like contraction began ( Figure 4D ). The engineered cardiac tissues maintained synchronous and tissue-like contraction for as long as 18 d of culture (Video S2, Supporting Information). Additionally, quantitative analysis of synchronous beats per minute (BPM) revealed that the constructs reached a maximum of 48 (± 20) BPM on day 10 (Video S3, Supporting Information) and a minimum of 13 (± 6) BPM on day 18 of culture. This variable beating behavior is consistent with previously reported studies on engineered GelMA-based cardiac tissues in vitro. [19, 30, 31] The decrease in beating rate with increasing culture time was also shown in previous studies, in which neonatal rat cardiomyocytes were cultured on hydrogelbased tissue-engineered models. [32, 33] In one of these studies, it was hypothesized that this decrease might be attributable to the phenotypical transition of fetal cardiomyocytes toward the neonatal stage. [33] We further examined the beating pattern of the beating constructs. As depicted in Figure 4E , the cardiac tissues showed a stable and regular beating pattern throughout culture days 4, 8, 12, and 16.
To assess physiological functionality of the engineered cardiac tissues, we also investigated the effect of a beta-adrenergic drug, isoproterenol (isoprenaline), on the beating behavior on day 6. Videos of the beating samples were recorded before and after 45 min incubation with 1 × 10 −6 m isoproterenol. An analysis of the videos revealed that the cardiac tissues exhibited physiological behavior in response to the drugs (Videos S4 and S5, Supporting Information). Figure 4F ,G shows the synchronous beating pattern (and amplitude) and beating frequency (in beats min −1 ), respectively, of the cardiac tissues before and after the drug administration. In the presence of isoproterenol, the cardiac tissues developed a significant increase in their spontaneous beating frequency ( Figure 4F ). Furthermore, an increase in the amplitude of all the samples was observed after exposure to the drug ( Figure 4G ).
TGF-β1 Induces Proliferation of Cardiac Fibroblasts
TGF-β1 is a well characterized protein in the pathophysiology of cardiac fibrosis, and is a potent stimulator of cardiac fibroblast proliferation during the course of this disease. [14] In order to assess the effect of TGF-β1 on cell proliferation within our engineered 3D cardiac tissues, we analyzed cell proliferation by EdU labeling. Fluorescent z-stack images of the EdU labeled cardiac tissues were taken on days 1, 7, and 14 of culture ( Figure 5A ). To identify the cellular phenotype of proliferating cells, we stained the cardiac fibroblasts by positive immunostaining for vimentin ( Figure 5A ). From Figure 5A , it is clear that the EdU labeled cells (green) were also positively stained by vimentin (red), thus confirming that the increase in proliferation across the two culture conditions was attributed to the proliferation of cardiac fibroblasts. Furthermore, a quantitative analysis of the percentage of EdU stained cells, revealed that the TGF-β1 treated samples showed a significantly higher number of EdU positive cells compared to the nontreated samples on days 1 and 7 ( Figure 5B) (p < 0.05). However, there was no significant difference on day 14 between the percentage of EdU positive cells in TGF-β1 treated (42 ± 11%) and nontreated samples (42 ± 10%). Additionally, the percentage of EdU labeled cells in the nontreated samples had a significant increase by day 14 (42 ± 10%) compared to day 1 (17 ± 4%) ( Figure 5B) (p < 0.05). A positive control analysis of the proliferation was also obtained by the EdU labeling of TGF-β1 treated and nontreated cardiac fibroblasts after 24 h of 2D-seeding in a wellplate ( Figure S2 , Supporting Information). As expected, the results were consistent with the results from the engineered cardiac tissues.
Characterization of the Expression of Cardiac Fibrosis Markers
Previous studies have demonstrated that quiescent cardiac fibroblasts spontaneously differentiate into activated MyoFs when cultured in 2D tissue culture polystyrene (TCPS) plates. [23, 60] This is thought to be partly due to the higher mechanical stiffness (GPa range) of TCPS compared to native and even fibrotic myocardium. [15, 34] Positive control of CF activation on www.advancedsciencenews.com www.advhealthmat.de TCPS conditions was obtained by culturing CFs in normal and TGF-β1 supplemented medium for 24 h. No significant difference was found in the expression of fibrotic markers (α-SMA, collagen-I, fibronectin, and MMP-2) after incubation of these CFs in normal medium compared to the TGF-β1 containing medium for 24 h ( Figure S3A ,B, Supporting Information). To investigate the activation of cardiac fibroblasts in a 3D beating heart-like environment and stiffness, we analyzed the expression of a specific MyoF protein marker, α-SMA after 14 d of culture ( Figure 6A ). As depicted in Figure 6A , cells in the cell-laden www.advancedsciencenews.com www.advhealthmat.de hydrogels showed a minimal expression of α-SMA, indicating that cardiac fibroblasts within the cardiac tissues remained in a quiescent state when cultured in normal culture medium. However, engineered 3D cardiac tissues cultured in the presence of TGF-β1, exhibited a more MyoF-like phenotype after 14 d, shown in Figure 6A . Furthermore, we analyzed the expression of other cardiac fibrosis markers by positive immunofluorescence staining of collagen-I, fibronectin, and MMP-2. Overall, confocal z-stack images clearly demonstrated an increased expression of fibronectin and collagen-I inside the engineered 3D cardiac tissues cultured in TGF-β1 supplemented medium. However, the expression MMP-2 was not clearly increased in the TGF-β1 treated samples. In addition to qualitative protein expression analysis, we also investigated the mRNA expression of α-SMA, collagen-I, fibronectin, and MMP-2 by quantitative real time polymerase chain reaction (RT-PCR) to confirm the upregulation of fibrotic protein expression in the TGF-β1 stimulated samples ( Figure 6B ). The expression levels of α-SMA, collagen-I, and fibronectin were shown to be elevated for TGF-β1 stimulated samples when compared to normal growth medium. The greatest increase was observed in the fibronectin samples, where the mRNA expression was 4 (± 2) (p < 0.05) times higher in the TGF-β1 treated samples as compared to the control group. Additionally, mRNA expression levels of α-SMA and collagen-I were shown to be 3 (± 1) (p < 0.05) and 3 (± 1) (p < 0.05) times higher, respectively, in TGF-β1 cultured samples as compared to control medium. However, as demonstrated by the protein expression analysis ( Figure 6A ), the expression of MMP-2 was not significantly changed in TGF-β1 stimulated samples (1 ± 0.5). Altogether, these results indicated that a quiescent cardiac fibroblast phenotype could be effectively cultured in a mechanically tuned GelMA-based cardiac tissue construct. Moreover, these results demonstrated that the phenotypic state of cardiac fibroblasts can be directed by designing a 3D cardiac tissue with a physiological co-culture of cells and an in vivo like dynamic contraction.
Analysis of the TGF-β1 Induced Pro-Fibrotic Changes
During fibrotic remodeling there is a higher risk of arrhythmogenicity as a result of an increased ECM deposition and an altered electrical-coupling between cardiomyocytes and MyoFs. [12, 35] In addition, human fibrotic cardiac tissue is hallmarked by an increased mechanical stiffness (≈30-70 kPa) when compared to healthy myocardial tissue (≈10 kPa). [36, 37] Furthermore, MyoFs can generate a higher contractile force than cardiac fibroblasts and thereby induce contraction and scarring of the cardiac tissue. We hypothesized that the engineered cardiac tissues would exhibit some of these fibrotic characteristics when the fibrotic response is simulated. To assess the pro-fibrotic changes, we cultured the samples in normal culture medium and added TGF-β1 for 14 d. All TGF-β1 stimulated cardiac tissues showed spontaneous individual cell beating from day 7 to day 13. Video analysis of the beating behavior revealed that there was a nonsynchronous and irregular contraction of all the tissues when stimulated with TGF-β1 ( Figure 7A and Video S6, Supporting Information). These results correlated well with previous reports that MyoFs induce changes in the beating behavior of cardiomyocytes. [12, 35] Compared with normal culture medium, we also observed a significant decrease of ≈17% in the average diameter of the GelMA-based cardiac tissues, thus indicating an increase in the MyoF-mediated contraction of the hydrogel ( Figure 7B ,C) (p < 0.05). In addition, SEM images of both culture conditions showed that cardiac tissues from TGF-β1 stimulated samples clearly had a more fibrous and fibrillar structure than cardiac tissues in the control group ( Figure 7D ). This is thought to be www.advancedsciencenews.com www.advhealthmat.de mainly attributable to the elevated deposition of ECM components (e.g., collagen-I, fibronectin) in the fibrotic-like tissues. On day 14, the mechanical stiffness of TGF-β1 treated engineered 3D cardiac tissues was compared to cardiac tissues cultured in normal culture medium. These measurements revealed an increase in the mechanical stiffness of TGF-β1 stimulated encapsulated cells in GelMA hydrogels ( Figure 7E ). Our findings highlight the opportunity to use these GelMAbased engineered 3D cardiac tissue constructs to identify fibrotic changes, and to study the pathophysiological cells and factors that play a role in cardiac remodeling and myocardial fibrosis.
Discussion
For many decades, conventional TCPS plates have successfully contributed to a better understanding of fibrogenesis in the context of cardiovascular diseases. However, these models lack the in vivo like presence of tissue-level properties (such as cell-ECM interactions). Furthermore, cardiac fibroblasts cultured in a 2D TCPS plate, spontaneously activate into MyoFs, thereby complicating the ability to study phenotypical changes of these cells during disease development. In this work, we designed a simplified 3D in vitro model of cardiac fibrosis by tuning the mechanical ECM of engineered cardiac tissues followed by stimulating these hydrogel-based tissues with TGF-β1; an established and potent mediator in fibrotic remodeling. [14] During cardiac fibrosis, there is an increased synthesis and deposition of ECM components, including collagen (mainly type I and III), laminin, fibronectin, and elastin. [4, 38] An increase in the expression of collagen-I and accumulation of fibrillar collagen deposition directly influences the structural integrity, biochemical, mechanical, and electrical properties of the cardiac tissue, and is considered as a hallmark of cardiac fibrosis. process, the main effector cells are activated MyoFs and proliferating cardiac fibroblasts. In addition, there is an increased (early phase remodeling) and decreased (late phase remodeling) production and activation of MMPs, which play a role in the degradation of the ECM. [28, 39] This is of importance since it can enable and facilitate the migration of cells (e.g., cardiac fibroblasts) to the area of injury at the early phases of wound healing. [40] The elevated expression of pro-fibrotic genes such as collagen-I, fibronectin, and α-SMA in our stimulated cardiac tissue was consistent with the pathological changes that occur during cardiac fibrosis. Similarly, we observed an activation of quiescent cardiac fibroblasts by positively immunostaining α-SMA; a widely used marker of MyoFs. [41] Immunostaining images further revealed that the TGF-β1 stimulated tissues also increased the expression of collagen-I and fibronectin. Our results also indicated that there was an induced proliferation of cells in the TGF-β1 treated cardiac tissues, as identified by EdU labeling. It is well established that TGF-β1 is an inducer of cardiac fibroblast activation during pathological fibrotic remodeling. [42] In addition, TGF-β1 is a proliferative stimulator of cardiac fibroblasts. [42, 43] Therefore, we investigated whether the proliferating cells are cardiac fibroblasts or cardiomyocytes by simultaneously labeling with EdU and immunostaining specifically for cardiac fibroblasts. Our results showed that the proliferating cells were cardiac fibroblasts rather than cardiomyocytes, which have a low proliferative capacity. [44] This disease model also showed that it could recapitulate functional properties of MyoFs and fibrotic cardiac tissue. TGF-β1 induced stimulation of the functional cardiac tissues resulted in an asynchronous and irregular beating behavior. Furthermore, the increased conversion of cardiac fibroblasts into MyoFs, resulted in a higher contraction and shrinkage of the 3D GelMA hydrogels. However, this could also be a result of degradation of GelMA hydrogel due to the production of various MMPs in the TGF-β1 stimulated tissues.
GelMA hydrogels have been a widely used scaffolding biomaterial in the past few years for applications ranging from tissue engineering, [30] organ-on-a-chip, [45] and in vitro disease models. [24] Previous studies have suggested that photocrosslinked cell-laden GelMA hydrogels are a suitable matrix to Adv. Healthcare Mater. 2017, 6, 1601434 Figure 7 . TGF-β1 induces pro-fibrotic changes, such as increased contractility of hydrogels, increased mechanical stiffness, and asynchronous beating, in 3D engineered cardiac tissues. A) Beating patterns of 3D engineered cardiac tissues cultured in NM (green) and NM + TGF-β1 (red) at day 7, 9, 11, and 13. The three red lines (solid and 3 dotted) represent three independently areas of beating within the same area of view. B) Hydrogel contraction test. Optical images of TGF-β1 treated and nontreated hydrogels with encapsulated cardiomyocytes and cardiac fibroblasts. C) Quantitative analysis of the contraction test of cardiomyocytes/cardiac fibroblast encapsulated GelMA hydrogels in NM compared to NM + TGF-β1. D) Representative scanning electron microscopy images of cell (white arrows)-encapsulated GelMA hydrogels cultured in NM and NM + TGF-β1 on day 14 of culture. E) Mechanical stiffness of the 3D cardiac tissues in the two different culture conditions (NM and NM+TGF-β1) at day 14 of culture. Data depict mean ± standard deviation. *p < 0.05.
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create functional tissue constructs. It has been reported that UV light alone at low intensity (6 or 4 mW cm −2 ) for several minutes does not affect cell viability and cell cycle significantly. [62] Furthermore, previous studies have suggested that photocrosslinked cell-laden GelMA hydrogels are a suitable matrix to create functional tissue constructs for various tissue engineering applications (such as cardiac and cartilage). [4,21,24,47,63a-c] Moreover, a high cell viability (>80%) after photocrosslinking of the cell-laden GelMA hydrogels has been reported in the literature. [47] Similarly, in this study, we observed a viability of >84% after 1 d of culture throughout all GelMA hydrogel conditions. Therefore, in this study, we do not expect that the exposure times used to adequately crosslink the GelMA (20 s) had a significant effect on cell viability and behavior. Additionally, most of the previous studies take advantage of the easy fabrication methods, high and easy accessibility, and high biocompatibility of GelMA hydrogels. [21] Moreover, GelMA hydrogels can be tuned mechanically to obtain a physiologically relevant stiffness. [21, 46] This can be obtained by varying the macromer concentration, the degree of methacryloyl modification, the concentration of photoinitiator (PI), the UV intensity, or the UV exposure time. [21] Although GelMA hydrogel is a semi-synthetic, photo-crosslinkable scaffolding material, it provides relevant biomimetic cues of the native ECM, such as RGD-binding peptides and MMP degradable sites. [47] In addition, gelatin is a denaturized form of collagen, which is the main constituent of native heart tissue, and therefore exhibits comparable biocompatible and biomimetic properties to collagen. However, a limitation of this in vitro system is the lack of other ECM components that are present in the native heart (e.g., collagens, glycosaminoglycans, laminin, and elastin). Interestingly, previous studies have shown that it is possible to engineer functional cardiac tissue by using naturally derived decellularized ECM from native heart tissues. [48] In a recent study, Visser et al. have combined the fabrication methods of GelMA molecules to engineer crosslinkable hydrogels derived from various native tissues. [49] Thus indicating that in future work, it could be possible to combine the advantages of GelMA hydrogels with the native properties of a decellularized heart ECM. Mechanotransduction is a process in which cells sense their mechanical microenvironment and transmit the physical stresses of their surroundings to biochemical signals that result in various cellular outputs (e.g., differentiation, proliferation). [50, 51] These mechanophysical signals are mainly mediated through cell-ECM and cell-cell interactions, which are converted to cellular signaling pathways by integrins, focal adhesions, and cadherins. [4, 50, 52] Cardiac fibroblasts and cardiomyocytes can sense their extracellular microenvironment by attaching to their ECM with focal adhesions. [53] Increasing ECM stiffness or ECM-induced strain, can affect both cardiomyocytes and cardiac fibroblasts in a way that alters contractile function and stimulates MyoFs activation. [15, 54] Consequently, the mechanical stiffness of the extracellular microenvironment of cardiac tissue is an important factor in both normal physiology and cardiac fibrosis. In fact, in a previous study by Engler et al. it was reported that cardiomyocytes cultured on stiff, fibroticlike (34 kPa) substrates, showed a decreased beating activity and lacked the development of well-striated sarcomere structures. [37] In addition, results from other recent studies have demonstrated that the mechanical stiffness of the matrix or substrate can facilitate the transition of cardiac fibroblasts into MyoFs. [22, 23] Zhao et al. engineered PEG-substrates with varying degrees of stiffness to study the migration, proliferation, and activation of quiescent cardiac fibroblasts in a 2D in vitro model system. [22] This culture platform suggested that the quiescent state of cardiac fibroblasts could be maintained and directed by mechanically tuning a hydrogel-based substrate. These results highlight the importance of the tunability of matrix stiffness for the engineering of functional and contractile cardiac tissues, while simultaneously maintaining the quiescent-like phenotype of cardiac fibroblasts. In this study, we used 7% MM-GelMA hydrogel (4.5 ± 0.8 kPa) to engineer a physiological stiffness in the same range of native neonatal rat hearts (4-11 kPa). [25] We showed that neonatal rat cardiac fibroblasts remained in a quiescent-state while co-cultured with cardiomyocytes in a mechanically tunable 3D hydrogel model.
Cardiac muscle is a syncytium in which a network of cardiomyocytes and cardiac fibroblasts are connected to each other electrically and mechanically. In order to engineer a physiologic-like heart tissue in vitro, it is essential for cardiomyocytes and cardiac fibroblasts to interact with each other through both direct, and indirect cell-cell and cell-ECM interactions. Here, we hypothesized that the spreading and networking of cells over time would lead to the development of a system, which better mimics native cardiac tissue. Consequently, 7% MM-GelMA hydrogel was selected as a 3D substrate for culturing cardiac fibroblasts and cardiomyocytes. The expression of cardiac differentiation markers (sarcomeric α-actinin, connexin-43) demonstrated a well-developed electrical coupling and contractile apparatus inside these hydrogel conditions. Although the cardiomyocytes had an isotropic orientation inside GelMA hydrogel, there was a clear elongation and a well-defined sarcomeric structure visible. In native cardiac tissue however, the cardiomyocytes are elongated and aligned in anisotropic layers of muscle tissue. [55] This is important for the anisotropic propagation of electrical signals, which plays a critical role in synchronous and rhythmic cardiac contraction. [56] One limitation of our engineered cardiac tissue was the lack of cellular anisotropic alignment, which could potentially lead to impaired electrical pulse propagation and contraction in comparison to the native heart muscle. In future studies, we could overcome this through the use of engineering strategies by applying topographical and electrical cues to the tissues to enhance the elongation and alignment of cells. [57] In this work, we used neonatal rat cardiomyocytes and cardiac fibroblasts to model an in vitro platform of myocardial fibrosis. Previous reports have shown evidence that neonatal cardiomyocytes possess several advantages over adult cardiomyocytes. [59a] In particular, neonatal rat cardiomyocytes seeded on hydrogel-based substrates exhibit spontaneous beating after seeding, whereas adult cardiomyocytes often require external electrical stimulation. [19, 31, 32] By enabling spontaneous contraction of the engineered tissue constructs, a more physiological mechanical cue could be added to the tissue constructs. Additionally, adult cardiomyocytes are terminally differentiated cells and therefore do not have the ability to proliferate in vitro. However, this would be desirable in a cardiac fibrosis model since activated cardiac fibroblasts may outgrow www.advancedsciencenews.com www.advhealthmat.de cardiomyocytes more readily, thereby complicating the ability to analyze the electrical changes of cardiac tissue during fibrogenesis. Furthermore, aging of the heart affects cardiac phenotype by inducing cellular hypertrophy and fibrotic changes. [59b,c] Consequently, an adult heart or a morphologically more fibrotic heart, may not be a suitable cell source to study the phenotypical changes that take place during fibrogenic remodeling. Moreover, different studies have exploited the use of neonatal rat cardiac fibroblasts as an in vitro model of myofibroblast differentiation, suggesting that neonatal rat heart cells are a suitable source for modeling this process. [59c,24] Additionally, the use of rats for in vitro studies of heart disease is the standard in both academia and pharmaceutical or biotechnology industry. Therefore, this indicates that our model may be a suitable and preclinically relevant in vitro platform for studies of pathophysiology and drug screening applications. However, we recognize the simplicity of this in vitro platform, as it lacks the incorporation of other dynamic (e.g., blood flow) and physiological factors (e.g., blood vessels, inflammatory cells), which are present in the native heart. Recently, microfluidic organ-on-a-chip have emerged and demonstrated the possibility of incorporating several dynamic factors (such as fluid flow and mechanical stretch) within microengineered cardiac tissues. [58] Further development of microfluidic techniques and tissue engineering strategies can therefore help in the development of a more physiologically relevant cardiac tissue in the future.
Conclusion
In this study, we engineered a simplified but functional and physiologic-like heart tissue to study cardiac fibrosis in a 3D GelMA-based hydrogel platform. By tuning the mechanical stiffness of GelMA hydrogels, we were able to create a welldefined and beating network of cardiomyocytes and quiescent cardiac fibroblasts. Subsequently, we showed that we were able to stimulate the activation of cardiac fibroblasts into MyoFs by addition of TGF-β1 to the culture medium. Furthermore, our results demonstrated that the engineered fibrotic-like tissues presented nonsynchronous beating behavior and mechanical alterations after incubation with TGF-β1. In particular, the fibrotic-like heart constructs demonstrated an increase in mechanical stiffness after 14 d of culture. In conclusion, our study presents a physiologic-like in vitro model of cardiac fibrosis that could enhance our understanding of this pathogenesis, while increasing the potential of these systems to be used for preclinical drug screenings.
Experimental Section
Synthesis of GelMA: GelMA was synthesized as described in a previous protocol. [21] Briefly, type A gelatin (10% (w/v)) from porcine skin (Sigma-Aldrich) was added to Dulbecco's phosphate buffer saline (DPBS; Gibco). This mixture was then stirred and heated at 50 °C for 1 h to obtain a clear gelatin solution. Subsequently, 1.25% (v/v) or 8% (v/v) methacrylic anhydride (Sigma-Aldrich) was added dropwise to synthesize MM and HM modification GelMA. The solution was stirred and remained on a hot plate for 1 h (middle methacryloyl modification) or 2 h (high methacryloyl modification), after which, DPBS was added to stop the reaction. Following this, the GelMA solution was dialyzed (molecular weight cut off: 12-14 kDa) with deionized water for 10 d at 40 °C to remove any salts and unreacted methacrylate anhydride. Finally, the GelMA solution was filtered (0.2 µm), frozen (−80 °C), and lyophilized for 5 d to obtain GelMA foam. The foam was stored at room temperature until further experimental use.
Preparation of Hydrogel Constructs: GelMA prepolymer solutions were prepared by dissolving 5%, 7%, and 10% (w/v) MM-and HM-GelMA in DPBS containing 0.25% (w/v) PI (Igracure 2595 Sigma). The solutions were briefly vortexed, and placed in an oven at 80 °C for 15 min to obtain prepolymer solutions of GelMA. To prepare disc-shaped hydrogels, 12 µL of the prepolymer solution was pipetted between two 600 µm tall spacers and covered with a 3-(trimethoxysilyl) propyl methacrylate treated glass-slide ( Figure S1 , Supporting Information). This prepolymer solution was placed into a customized UV-chamber and exposed to UV light (800 mW, 360-480 nm) for 20 s, resulting in the creation of 600 µm tall hydrogel discs ( Figure S1 , Supporting Information). After this, the GelMA hydrogels were removed manually from the glass slide and utilized for further experiments.
Cardiac Cell Isolation and Culture: Primary ventricular cardiomyocytes and cardiac fibroblasts were isolated from 2 dold neonatal Sprague Dawley rats. These procedures were based on a previously well-defined protocol approved by the Institution's Committee on Animal Care. [33] Briefly, the hearts of neonatal pups were surgically removed from the thoracic cavity after euthanasia. Upon removing the atria, the ventricular tissues were cut into multiple small pieces and incubated overnight (at 4 °C) on a shaker in a 0.05% (w/v) trypsin solution prepared in Hank's balanced salt solution (HBSS, Gibco, USA). The heart tissues were subjected to four collagenase type II (LS004176, Worthington, Lakewood, NJ) digestions (10 min, 37 °C, 80 rpm) to further digest the heart tissues. The cell suspension was then collected, centrifuged (1000 rpm) for 5 min, and preplated for 1 h to enrich the cardiomyocytes for immediate experimental use. The attached cardiac fibroblasts were cultured for a maximum of three passages for future experimental use. The cardiac fibroblasts were cultured in Dulbecco's modified eagle medium (DMEM, Gibco USA) with 10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin/streptomycin (P/S; Gibco, USA). To identify the purity of cardiomyocytes, the authors performed fluorescence-activated cell sorting (FACS) using Troponin-T as a cardiomyocyte specific marker immediately after cell isolation. The data indicated that the authors had successfully obtained 77.3% Troponin positive cells, which they further used to adjust the concentration of cardiac fibroblasts to achieve a final cardiomyocyte:cardiac fibroblast ratio of 1:1 ( Figure S4 , Supporting Information). In the previous study, the authors had demonstrated that a co-culture of cardiomyocyte:cardiac fibroblast (1:1) exhibit cardiac-like tissue functions such as spontaneous beating, gap-junction expression and sarcomeric structure. [61] Engineering Cell-Laden Hydrogel Constructs: To fabricate cell-laden hydrogel constructs, a prepolymer solution was prepared with minor modifications to the described protocol above. In brief, 5%, 7%, and 10% (w/v) MM-and HM-GelMA was dissolved in DMEM containing 0.25% PI, 50% FBS, 1% P/S, and 2% (w/v) l-glutamine (Gibco USA). Prepolymer solutions were removed from the 80 °C oven, and placed in a water bath at 37 °C until cell encapsulation. Cultured cardiac fibroblasts (passages 1-3) were trypsinized and mixed at a 1:1 ratio with the freshly isolated cardiomyocytes to obtain a final concentration of 25 × 10 6 cells mL . The cells were centrifuged at 1200 rpm for 5 min, and the pellet was resuspended in the GelMA prepolymer solution. Gels were created following the preparation of hydrogel constructs (above) and placed in culture medium containing DMEM, supplemented with 10% FBS, 1% P/S, and 2% l-glutamine. In some conditions, media was additionally supplemented with TGF-β1 at a concentration of 2 ng mL −1 (100-21C, PeproTech, USA) Medium was replaced consistently every 24 h throughout all experimental conditions.
Characterization of Hydrogels and Engineered Cardiac Tissues: Hydrogels were fabricated according to the described methods above to determine the compressive modulus of the constructed (cell-laden) hydrogels. After fabrication, noncell-laden hydrogels were detached from the glass slide and allowed to swell overnight in DPBS at 4 °C. Engineered cardiac tissues, however, were cultured in normal and TGF-β1 containing medium for 14 d before mechanical testing (n = 5). Hydrogels were cut with a 5 mm biopsy punch, and excess liquid was removed from the hydrogel. Gels were compressed with a uniaxial tensile loading machine (Instron, 5542, USA) at a rate of 1 mm min −1 with a 10 N cell load capacity. The compressive modulus was calculated as the slope from 0%-15% strain (n = 4). SEM (Zeiss Ultra 55 SEM; Carl Zeiss, Thornwood, NY, USA) was performed to characterize the hydrogel porosity. Cell-laden hydrogels were fixed at day 1 and day 14 in 4% (v/v) paraformaldehyde (PF, 15700, Electron Microscopy Sciences, Hatfield, PA) for 30 min at room temperature. Following fixation, the cell-laden hydrogels were washed with DPBS and incubated at 4 °C overnight. Hydrated hydrogels were placed in liquid nitrogen for 20 min and stored at −80 °C overnight. After freezing, the hydrogels were lyophilized for 2 d to obtain a porous and foam-like GelMA hydrogel. The foams were broken in half and coated with Pt/Pd to allow for cross-sectional imaging by SEM. Quantification of the pore-size was performed by measuring pore-size diameter (n = 150) from SEM images (n = 3) made from 5% HM, 7% MM, and 10% MM-GelMA foams.
Hydrogel degradation was assessed by fabricating hydrogels and subjecting them to collagenase-induced degradation. Hydrogels were fabricated and allowed to swell in DPBS overnight at 4 °C. Hydrogels were then placed in a 0.5 U mL −1 collagenase type II solution (in DPBS) at 37 °C. Excess liquid was removed, and the hydrogels were weighed before and after incubation with collagenase. The weight loss percent was determined after 0.5, 1, 3 and 6 h (n = 3).
Characterization of Cell Spreading and Cell Viability: Cell spreading within the 3D engineered cardiac tissues was determined by visualizing the organization of F-actin fibers within the cells. The cell-laden hydrogels were fixed with 4% PF solution for 30 min. Subsequently, the 3D encapsulated cells were permeabilized with 0.1% X-100 Triton (Sigma-Aldrich) for 40 min at room temperature. This was followed by 45 min incubation with Alexa Fluor 488 Phalloidin (Invitrogen) with a 1:40 dilution in DPBS. Cell nuclei were counterstained with 4′,6-diamidino-2-phenyl indole dihydrochloride (DAPI; Vector Laboratories) for 20 min at room temperature. Hydrogels were then washed three times in DPBS for 5 min. 3D imaging was performed by confocal microscopy (Leica SP5 X MP, Germany) to visualize the fluorescently stained F-actin fibers and to determine the degree of cell spreading within the hydrogels. Z-stack (100 µm each) images were taken of each hydrogel per condition and four areas (400 µm × 400 µm) were selected for further quantification of cell spreading. Fractional area coverage by F-actin was determined within the four selected windows using ImageJ software.
Cell viability was examined with a Live/Dead fluorescent labeling kit (Invitrogen) on day 1 of culture according to the manufacturer's protocol. Hydrogels were first washed with DPBS followed by an incubation with calcein-AM (0.5 µL mL −1 ) and ethidium homodimer-1 (2 µL mL −1 ) in DPBS for 15 min at 37 °C. After washing with DPBS, fluorescent images were taken from four selected areas using an inverted microscope (Nikon TE 2000-U, Nikon instruments Inc., USA). To quantify viability, images were taken at four different focal planes within the hydrogel by adjusting the height of the objective manually. Three cell-laden hydrogels were used to determine the cell viability in each condition, and ImageJ software was used to quantify the number of viable cells. Data depicted represents the percentage of live cells within the engineered constructs. Cell metabolic activity was assessed throughout culture with PrestoBlue Cell Viability Reagent (PB; Life Technologies). The cell-laden hydrogels were incubated with PrestoBlue for 2 h at 37 °C in a 1:10 dilution in normal culture medium (n = 4). The fluorescence was determined (560-590 nm) using a fluorescence reader (Synergy HT-Reader, BioTek, Winooski, VT). The data was normalized to hydrogel samples without encapsulated cells. The data represent the normalized fluorescence absorbance at days 1, 5, 10, and 14 of culture.
Cell Proliferation Analysis: Click-iT Plus EdU Alexa Fluor 488 Imaging Kit (Life Technologies) was used to specifically and quantifiably assess the number of proliferating cells within 3D cardiac tissues. Proliferating cells were labeled following the manufacturer's guidelines. Briefly, cellencapsulated hydrogels (n = 3) were incubated with 10 × 10 −6 m EdU in normal culture medium at 37 °C. After 24 h of incubation, the samples were fixed with 4% PF (30 min) and permeabilized with 0.1% X-100 Triton (40 min) at room temperature. The samples were blocked with 3% (w/v) bovine serum albumin (Sigma-Aldrich) solution and subsequently incubated for 30 min with the Click-iT solution at room temperature. Additionally, cell-specific proliferation was assessed by immunostaining with vimentin, a mesenchymal cell specific marker. Subsequently, the samples were washed twice with DPBS and counterstained for 20 min with DAPI at room temperature. 3D z-stack (50 µm each) images were taken by confocal microscopy. To quantify proliferation, fluorescence images were taken with an inverted microscope at three different focal planes within the hydrogel by adjusting the height of the objective manually (n = 3). ImageJ software was used to count the number of EdU positive cells. Positive control for EdU labeling was determined by staining cardiac fibroblasts cultured for 24 h in normal, and TGF-β1 supplemented culture medium (n = 3). Fluorescence images were taken from each sample by using an inverted microscope (n = 10). The percentage of proliferating cells was calculated by counting the EdU labeled cells using ImageJ software. Cell proliferation was calculated by dividing the EdU positive cells by the total number of DAPI positive cells.
Immunofluorescence Staining for Cardiac (Fibrosis) Specific Markers: The 3D engineered cardiac tissues were immunostained for cardiac tissue (sarcomeric α-actinin, connexin-43) and cardiac fibrosis (α-SMA, collagen type I, fibronectin, and MMP-2) markers. Samples were fixed with a 4% PF solution for 30 min, followed by three washing steps (5 min each) with DPBS. Subsequently, the cell-hydrogels were permeabilized by incubation with 0.1% X-100 triton for 45 min, after which the samples were washed with DPBS and blocked for 30 min with a 10% goat serum solution in DPBS. After blocking, the hydrogels were incubated with a monoclonal mouse anti-sarcomeric α-actinin (Abcam, catalogue #9465), polyclonal rabbit anti-connexin-43 (Abcam, catalogue #11370), monocloncal rabbit anti-vimentin (Abcam, catalogue #92547), monoclonal rabbit anti-α-SMA (Abcam, catalogue #32575), polyclonal rabbit anti-collagen I (Abcam, catalogue #292), polycloncal rabbit anti-fibronectin (Abcam, catalogue #23751), or a polycloncal rabbit anti-MMP-2 (Abcam, catalogue #37150) for 16 h at 4 °C. After incubation with the primary antibody (diluted 1:200 in 10% goat serum), the samples were washed three times (10 min each) in DPBS at room temperature. The secondary antibodies (goat anti-rabbit Alexa Fluor 594 or goat anti-mouse Alexa Fluor 488 (Abcam)) were diluted 1:200 in 10% goat serum, followed by incubation with the samples for 2 h at room temperature. The nuclei were counterstained with DAPI. Immunofluorescence double staining was performed by incubating two primary antibodies (e.g., sarcomeric α-actinin and connexin-43) simultaneously. After washing with DPBS three times, the secondary antibodies were incubated separately for 2 h each. 3D confocal z-stack images (150 µm each) were taken and processed with ImageJ software.
Characterization of the Beating Behavior of Engineered Cardiac Tissue:
The beating behavior of 3D engineered cardiac tissues was characterized quantitatively by using a temperature controlled chamber (at 37 °C) and real time video recording with a camera (Sony XCD-X710) attached to an inverted optical microscope. Videos of the beating constructs (n = 3) were recorded every day from day 3 of culture onward in three different constructs at three different spots. The beating pattern and frequency of the constructs was determined by a custom written MATLAB program. [59] The single cell beating characteristics of the engineered tissues, cultured in growth medium supplemented with TGF-β1, were also assessed with a modified custom written MATLAB program.
GelMA Hydrogel Contraction Assay: A GelMA hydrogel contraction assay was performed to assess the contractile manifestation of MyoFs inside the engineered fibrotic-like cardiac tissues. The GelMA hydrogel contraction assay was performed in a similar manner as a previously described collagen contraction assay. [22] Briefly, 3D cell-laden hydrogels were fabricated as described above and were cultured in TGF-β1 containing culture medium for 14 d according to the protocol. After 14 d, the culture medium was aspirated and optical images were taken, followed by a quantitative analysis of the gel diameters using ImageJ software. Depicted data represents mean ± SD of gel diameter in each condition (n = 5).
Real-Time Polymerase Chain Reaction for Expression of Cardiac Fibrosis Markers:
Cell-laden hydrogels were used to examine the expression of cardiac fibrosis markers. First, 3D cardiac tissues were mechanically disrupted and total RNA was extracted from all samples using TRIzol reagent (Life Technologies) and total RNA yield was measured with a NanoDrop (Thermo Scientific). 1 µg of total RNA from each sample was reverse transcribed according to the manufacturer's instructions using the QuantiTect Reverse Transcription kit (Qiagen). All RT-PCR was performed using the iTaq Universal SYBR Green supermix (Bio-Rad, USA). The 20 µL volume reaction component included 10 µL supermix, 1 µL of primer mix (5 × 10 −6 m forward/reverse primer), 100 ng template and nuclease free water (variable). Predesigned KiCqStart SYBR Green primers (Sigma-Aldrich) were obtained for the following target genes: Collagen1A1 (catalogue #KSPQ12012G), Fibronectin (catalogue #KSPQ12012G), α-SMA (catalogue #KSPQ12012G), and MMP-2 (catalogue #KSPQ12012G). Relative expressions were calculated using ΔΔCt method and normalized to glyceraldehyde-3-phosphate dehydrogenase gene expression.
Statistical Analysis: The quantitative results on all sample conditions were plotted by mean ± standard deviation (error bars). Investigators blinded to the various treatment conditions assessed and analyzed the measurements related to mechanical stiffness, RT-PCR, and all quantitative analysis. To perform statistical analysis, a Student's t-test or one-way analysis of variance (ANOVA) was used. For multiple comparisons, we used a Tukey's test. Graphpad Prism (v.6, GraphPad, USA) software was used to perform all statistical analyses and results were considered to be significantly different with a p < 0.05.
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